Academisch Ziekenhuis Leiden
Verified site
Leiden, The Netherlands
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on individuals with Chronic Hypoparathyroidism, a rare condition in which the parathyroid glands do not make enough hormone, resulting in low calcium levels in the blood. The medication being tested is Encaleret, an oral tablet taken by mouth, and it is compared with a matching placebo. The aim is to determine whether the drug can increase the amount of calcium in the blood and reduce the amount of calcium that is excreted in the urine over a 24‑hour period.
The purpose of the study is to show the effectiveness of the drug in improving calcium balance. Participants will be randomly assigned to receive either the active tablet or the placebo for several months, with regular visits to monitor blood calcium, urine calcium, and any side effects. After the initial blinded phase, participants may enter an open‑label extension where everyone receives the active medication, allowing longer‑term safety and tolerability information to be gathered.
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
4 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Leiden, The Netherlands
Rotterdam, The Netherlands
Paris, France
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Encaleret is an oral, film‑coated tablet that contains the active ingredient encaleret hemisulfate hemihydrate. It is being studied as a treatment for chronic hypoparathyroidism, a condition where the body does not produce enough parathyroid hormone, leading to low calcium levels. In the trial, participants take the tablet to see if it can raise the amount of calcium in the blood and reduce the amount of calcium lost in the urine. The study will check how well the medicine works and whether it is safe and tolerable for patients.
A condition in which the parathyroid glands produce insufficient amounts of parathyroid hormone, leading to low levels of calcium in the blood. Without enough hormone, calcium is not released from bones or reabsorbed by the kidneys, causing a gradual decline in blood calcium. Symptoms may develop slowly as calcium levels fall, affecting muscle function and nerve signaling. Over time, the body attempts to compensate, but calcium remains below normal. The low calcium state can persist unless the underlying hormone deficiency changes.
A long‑lasting form of hypoparathyroidism that continues for months or years after the initial hormone deficiency appears. The persistent lack of parathyroid hormone keeps blood calcium consistently low, and the body does not recover on its own. Calcium balance remains abnormal, leading to ongoing adjustments in bone and kidney handling of minerals. The condition typically follows an initial acute phase and then stabilizes at a reduced calcium level. It remains present until an effective intervention alters hormone production or calcium regulation.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.